Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for fistulizing perianal Crohn's disease
NL-OMON60557Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of guselkumab in Crohn's disease and anal fistula, sponsored by Janssen Pharmaceutical. Primary endpoint: Combined fistula remission at Week 24. Started Nov 2022; status: completed.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on NL-OMON60557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60557.